OGT expands NGS cancer panel offering

February 2021—Oxford Gene Technology has expanded its SureSeq range of next-generation sequencing panels to include a comprehensive myeloid panel and a breast and ovarian cancer panel that incorporate copy number variation detection.

The SureSeq Pan-Myeloid panel includes 70 key genes implicated in a wide range of myeloid disorders, including acute myeloid leukemia, myeloproliferative neoplasms, and myelodysplastic syndrome.

The panel provides excellent coverage uniformity to detect clinically relevant single nucleotide variants and indels down to one percent variant allele frequency. *CEBPA, JAK2, CALR*, and *MPL*, and other genes are included in the panel, and regions containing hard-to-detect structural variants such as FLT3-ITDs and KMT2A-PTDs are covered.

The SureSeq Breast Cancer plus CNV panel detects indels, SNVs, and CNVs and offers 100 percent concordance with multiplex ligation-dependent probe amplification. The panel targets BRCA1, BRCA2, ATM, TP53, CHEK2, PALB2, and PTEN, and is able to detect CNVs ranging from single exons to full gene deletions and duplications.

The panels have been designed based on the most recent literature, the company reports, and with input from recognized cancer experts.

Oxford Gene Technology, +44 (0) 1865 856800